MedPath

Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis

Phase 3
Completed
Conditions
Graves Disease
Atherosclerosis of Artery
Pathophysiology
Hyperthyroidism
Interventions
Registration Number
NCT05118542
Lead Sponsor
Indonesia University
Brief Summary

During July 2019 to August 2020, a single-blind clinical trial was done to 36 patients with Graves' disease. At the beginning of the study, subjects were accommodated into 2 groups, 17 into PTU groups and 19 into methimazole groups. There were 24 subjects who finished the study, 13 from PTU group and 11 from methimazole group. Blood serum was collected for HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin examination. Meanwhile stiffness and thickness of carotid artery was measured using PWV and cIMT.

Detailed Description

This study was a single blind, randomized clinical trial study, conducted in Cipto Mangunkusumo National Referral Hospital from January 2019 to August 2020. We included all adult patient aged 18-65 years with newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month, who agreed to participate in the study. The exclusion criteria was pregnancy, history of coronary heart disease, known malignancy, current use of immunosuppressive medication, sepsis, thyroid crisis, or having allergic reaction to anti-thyroid drugs and other severe side effect. Ethical approval was obtained from the Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia with approval number KET-784/UN.2.F1/ETIK/PPM.00.02/2019.

Study participant was observed every month for 3 months. Anti-thyroid drugs (PTU or methimazole) were given according to true simple randomization with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist. At baseline visit, first and third month follow up, blood serum was collected to analyse HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin, meanwhile PWV and cIMT were measured using radiofrequency ultrasound examination of carotid arteries.

Categorical data was presented in frequency (%), while numerical data was presented using mean (SD) if normally distributed or median (IQR) if not normally distributed. Correlation Pearson test was performed for normal distributed data and Spearman test for not normal distributed data. To analyze the changes in parameter from baseline, first and third month, repeated ANOVA and General Linear Model test was performed. For not normally distributed data, transformation into normally distributed data was performed and the data was presented as geometric mean (CI 95%).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Adult patients aged 18-65 years
  • Newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month
  • Agreed to participate in the study
Exclusion Criteria
  • Pregnancy
  • History of coronary heart disease
  • Known malignancy
  • Current use of immunosuppressive medication sepsis, thyroid crisis
  • Having allergic reaction to anti-thyroid drugs and other severe side effect

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Methimazole GroupMethimazoleMethimazole was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
PTU GroupPropylthiouracilPropylthiouracil (PTU) was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
Primary Outcome Measures
NameTimeMethod
carotid intima media thicknessChange from Baseline to 3 month follow-up

cIMT was measured using radio frequency ultrasound in supine position at both left and right carotid artery

Pulse Wave VelocityChange from Baseline to 3 month follow-up

Pulse wave velocity was measured using radio frequency ultrasound in supine position at both left and right carotid artery

Secondary Outcome Measures
NameTimeMethod
HOMA-IRChange from Baseline to 3 month follow-up

HOMA-IR was calculated from patient fasting blood glucose and fasting insulin, which both were obtained through serum of the patient. Fasting blood glucose was measured using ECLIA methods with Abbott reagent, while fasting insulin were measured using ELISA with D\&G International Inc. kit

LDL-RChange from Baseline to 3 month follow-up

LDL-R was measured from the patient serum using ELISA with D\&G International Inc. kit

NFkBChange from Baseline to 3 month follow-up

NFkB was measured from the patient serum using ELISA with Cusabio kit

sVCAM-1Change from Baseline to 3 month follow-up

sVCAM-1 was measured from the patient serum using ELISA with D\&G International Inc. kit

sE-selectinChange from Baseline to 3 month follow-up

sE-selectin was measured from the patient serum using ELISA with D\&G International Inc. kit

sICAM-1Change from Baseline to 3 month follow-up

sICAM-1 was measured from the patient serum using ELISA with D\&G International Inc. kit

Trial Locations

Locations (1)

University of Indonesia

🇮🇩

Jakarta Pusat, Jakarta, Indonesia

© Copyright 2025. All Rights Reserved by MedPath